Essex Bio-Technology Limited (HK:1061)
:1061
Want to see HK:1061 full AI Analyst Report?
1061 Stock Chart & Stats
HK$3.81
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.81
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.55 - HK$6.12
Previous CloseN/A
Volume76.00K
Average Volume (3M)863.25K
Market Cap
HK$1.53B
Enterprise ValueHK$1.12B
Total Cash (Recent Filing)HK$784.14M
Total Debt (Recent Filing)HK$346.90M
Price to Earnings (P/E)4.9
Beta0.59
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)0.56
Shares Outstanding567,006,000
10 Day Avg. Volume975,600
30 Day Avg. Volume863,250
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)0.89
Price to Sales (P/S)1.18
P/FCF Ratio16.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.84Price Target Upside79.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.87B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained 85%–90% gross margins indicate durable product-level economics and pricing power in biologics. Such margins provide a large earnings buffer against cost inflation, support sustained R&D and commercial investment, and underpin long-term operating profitability across cycles.
Conservative, Improving LeverageA falling debt-to-equity trend and meaningful equity buildup provide financial flexibility. Low leverage reduces default and refinancing risk, supports funding for product launches or M&A, and strengthens resilience to sector downturns over the medium term.
Consistent Positive Operating Cash FlowRecurring positive operating cash flow shows the business converts core earnings into cash, supporting ongoing operations, working-capital needs, and baseline reinvestment or dividends. This cash-generative profile is a durable sign of underlying business quality.
Bears Say
Volatile Free Cash FlowLarge swings in free cash flow reduce predictability of capital allocation and constrain consistent reinvestment, dividends, or M&A. A near-50% FCF drop in 2025 suggests sensitivity to capex or working-capital moves, raising medium-term execution risk.
Choppy Revenue MomentumIrregular top-line trends indicate demand or commercial execution volatility across periods. This uneven revenue base complicates scaling costs, forecasting, and ROI on new product launches, and may limit sustainable growth over the next several quarters.
Execution Risk From FCF Decline And Rising Absolute DebtManagement faces execution pressure: earnings are profitable but the combination of a sharp FCF decline and uneven revenues increases risk to sustaining shareholder returns and funding strategic initiatives. This constrains long-term reinvestment predictability.
Essex Bio-Technology News
1061 FAQ
What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$2.55 and its highest was HK$6.12 in the past 12 months.
What is Essex Bio-Technology Limited’s market cap?
Essex Bio-Technology Limited’s market cap is HK$1.53B.
When is Essex Bio-Technology Limited’s upcoming earnings report date?
Essex Bio-Technology Limited’s upcoming earnings report date is Sep 01, 2026 which is in 75 days.
How were Essex Bio-Technology Limited’s earnings last quarter?
Essex Bio-Technology Limited released its earnings results on Mar 23, 2026. The company reported HK$0.273 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.273.
Is Essex Bio-Technology Limited overvalued?
According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Undervalued.
Does Essex Bio-Technology Limited pay dividends?
Essex Bio-Technology Limited pays a Quarterly dividend of HK$0.07 which represents an annual dividend yield of 3.37%. See more information on Essex Bio-Technology Limited dividends here
What is Essex Bio-Technology Limited’s EPS estimate?
Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Essex Bio-Technology Limited have?
Essex Bio-Technology Limited has 567,006,000 shares outstanding.
What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
Essex Bio-Technology Limited reported an EPS of HK$0.273 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.013%.
Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
Currently, no hedge funds are holding shares in HK:1061
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Essex Bio-Technology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$6.84 (79.53% Upside)
HK$6.84 (79.53% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.30%
12-Months-Change
Fundamentals
Return on Equity
13.57%
Trailing 12-Months
Asset Growth
17.02%
Trailing 12-Months
Company Description
Essex Bio-Technology Limited
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.
1061 Stock 12 Month Forecast
Average Price Target
HK$6.84
▲(79.53% Upside)
Technical Analysis
Hua Medicine
―
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―
Options Prices
Currently, No data available
---